带手工缝制三尖瓣的肺动脉ePTFE管道多中心回顾研究
OBJECTIVES: The biocompatibility of expanded polytetrafluoroethylene in the pulmonary position seems better than allogenic or xenogeneic reactivity.…
要点
- 5年与10年免于管道置换率分别为98%和83%,5次置换均因18mm管道狭窄。
- 24mm管道在体重≤75kg、体表面积≤2.0m²患者术后>12年峰值流速<3.0m/s且无中重度反流。
核心结论
- 带手工缝制三尖瓣的肺动脉ePTFE管道临床结局良好,是现有产品早期衰败风险高的年轻患者的有效替代选择。
研究设计与样本
- 瓣叶材料为0.1mm厚ePTFE膜,管道材料为标准壁ePTFE管。
主要发现
- 中位手术年龄12岁(范围1.2-40岁),中位体重34kg(范围9.1-82kg)。
- 18、20、22、24mm管道分别用于19、5、3、57例患者。
- 5年与10年总体生存率均为94%,4例死亡非瓣膜相关。
- 5年与10年免于管道置换率分别为98%和83%,5次置换均因18mm管道狭窄。
- 5年与10年免于管道狭窄≥中度分别为83%和54%,免于肺动脉反流≥中度均为98%。
关键数值与推荐
- 线性混合效应模型提示24mm管道在体重≤75kg、体表面积≤2.0m²患者术后>12年峰值流速<3.0m/s且无中重度反流。
临床怎么用
- 该管道可作为肺动脉位置重建的替代选择,尤其适用于现有产品早期衰败风险高的年轻患者。
- 18mm管道狭窄与置换风险较高,选择尺寸时需权衡患者体型与远期通畅性。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The biocompatibility of expanded polytetrafluoroethylene in the pulmonary position seems better than allogenic or xenogeneic reactivity. This study reviewed the application of pulmonary expanded polytetrafluoroethylene conduits having a hand-sewn tricuspid valve with diameters of 18-24 mm. METHODS: All patients receiving this conduit between 2010 and 2022 were evaluated. A 0.1-mm-thick membrane and a standard-wall tube of expanded polytetrafluoroethylene were used for cusp and conduit material, respectively. RESULTS: Eighty-four consecutive patients were included. The median operative age and weight were 12 (range, 1.2-40) years and 34 (range, 9.1-82) kg, respectively. Eighteen-, 20-, 22- and 24-mm conduits were used in 19, 5, 3 and 57 patients, respectively. The overall survival was 94% at 5 and 10 years with four non-valve-related deaths. There were five conduit replacements, all for 18-mm conduit stenosis. Freedom from conduit replacement was 98% and 83% at 5 and 10 years, respectively. Freedom from conduit stenosis ≥ moderate was 83% and 54% at 5 and 10 years, respectively. Freedom from pulmonary regurgitation ≥ moderate was 98% at 5 and 10 years. Linear mixed-effects models with echocardiographic data implied that 24-mm conduits functioned with a peak velocity <3.0 m/s and without moderate/severe regurgitation in patients with a body weight of up to 75 kg and a body surface area of up to 2.0 m2 for >12 years postoperatively. CONCLUSIONS: This conduit has shown favourable clinical outcomes and is a valid alternative, especially in young patients with increased risk for early failure of the existing products.
引用
- Matsushima S, Takahashi R, Kubo S, et al. Pulmonary expanded polytetrafluoroethylene conduits with a hand-sewn tricuspid valve. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 39909862. doi:10.1093/icvts/ivaf020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。